If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

Having asthma, Hashimoto’s thyroiditis or atopic dermatitis in addition to alopecia areata raised the odds for early-onset, severe and prolonged alopecia areata, according to a research letter ...

Exhaled Nitric Oxide and Sputum Eosinophils are Complementary Tools for Diagnosing Occupational Asthma suggests a study ...

A study reveals that shape-shifting immune cells, intermediate ILC2s, may contribute to severe asthma and resistance to ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- A set of chameleon-like immune cells could be contributing to severe asthma in ...

Asthma represents a substantial health burden in childhood globally, with minoritised populations being disproportionately impacted.1 Recent literature has increasingly linked social determinants of ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

A simple, noninvasive nasal swab identified a predominance of T2-low asthma subtypes in racial and ethnic minority pediatric ...

Eosinophils, traditionally recognized for their role in allergic diseases and parasitic infections, have emerged as pivotal players in the pathophysiology ...

Nasal epithelial gene expression can be used to characterize asthma endotypes and reveals that most participants from 3 studies of youths with asthma have nasal transcriptomic profiles with low T2 ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...